

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2022/2023 influenza season

as of June 18, 2025

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	1 (1.2%)	1 (0.8%)	1 (0.8%)	0	0	75 (100%)	12 (1.9%)	0	0	0	0	338 (100%)	0	0	0	0	0
Number of viruses tested	83	119	119	73	73	75	616	331	331	331	331	338	51	49	49	49	49
Number of viruses reported	212						3,610						90				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.